Oncology journals by time to acceptance (2025)
98 journals with 2025 figures · median days from submission to acceptance, measured from PubMed dates · data as of Sep 15, 2026
Sorted by median days from submission to acceptance in 2025. Faster is not better — this is a planning aid, not a ranking of quality. Click a column to re-sort.
| Open access | ||||||
|---|---|---|---|---|---|---|
| Anti-Cancer Drugs | 0 (0–1) | 53 | 63 | — | — | 1.34 |
| Anticancer Research | 24 (17–35) | 585 | — | — | Hybrid | 0.63 |
| Cancer Diagnosis & Prognosis | 24 (19–33) | 99 | 53 | — | — | 0.0 |
| In Vivo | 26 (18–38) | 347 | — | — | Open access | 3.1 |
| Cancers | 38 (29–49) | 3,955 | 3 | ≈$3,499 | Open access | 0.23 |
| Current Oncology | 45 (35–57) | 692 | 3 | ≈$2,689 | Open access (DOAJ) | 0.0 |
| Journal of Cancer Research and Clinical Oncology | 47 (31–89) | 297 | 20 | $4,390 | Open access (DOAJ) | 3.63 |
| Journal of Cancer Education | 59 (39–94) | 88 | 15 | ≈$3,790 | — | 0.0 |
| Investigational New Drugs | 59 (39–84) | 85 | 17 | ≈$4,690 | — | 0.0 |
| World Journal of Oncology | 59 (45–73) | 67 | 23 | — | Open access | 3.39 |
| The Lancet Oncology | 60 (7–101) | 265 | 59 | ≈$7,280 | — | 1.48 |
| Współczesna Onkologia | 61 (45–93) | 52 | 74 | ≈$439 | Open access (DOAJ) | 0.0 |
| Cancer Treatment Reviews | 64 (46–92) | 126 | 2 | ≈$4,910 | Hybrid | 0.0 |
| Clinical & Translational Oncology | 65 (39–106) | 349 | 24 | ≈$4,690 | — | 0.0 |
| Critical Reviews in Oncology/Hematology | 67 (37–118) | 398 | 3 | ≈$4,190 | Hybrid | 0.0 |
| European Journal of Cancer | 71 (49–102) | 388 | 6 | ≈$4,270 | Hybrid | 0.0 |
| Oncology and Therapy | 72 (51–118) | 76 | 25 | $7,675 | Open access (DOAJ) | 0.0 |
| European Journal of Oncology Nursing | 75 (52–121) | 265 | 2 | ≈$3,790 | — | 0.0 |
| World Journal of Gastrointestinal Oncology | 78 (63–101) | 357 | — | — | Open access | 0.0 |
| Case Reports in Oncology | 78 (56–114) | 210 | 18 | $1,200 | Open access (DOAJ) | 1.82 |
| Annals of Oncology | 78 (44–132) | 127 | 10 | ≈$5,080 | Hybrid | 1.97 |
| Neoplasia | 79 (43–117) | 133 | 8 | $3,790 | Open access (DOAJ) | 1.88 |
| Annals of Coloproctology | 80 (54–109) | 79 | 132 | $500 | Open access (DOAJ) | 0.0 |
| Medical Oncology | 81 (67–106) | 603 | 16 | ≈$4,290 | — | 4.27 |
| Case Reports in Oncological Medicine | 81 (58–138) | 76 | 23 | $870 | Open access (DOAJ) | — |
| Journal of Cancer Policy | 82 (42–119) | 106 | 3 | ≈$2,760 | — | 3.07 |
| Breast Cancer Research and Treatment | 84 (57–127) | 266 | 17 | ≈$4,190 | Hybrid | 0.0 |
| Seminars in Oncology | 84 (56–109) | 73 | 33 | ≈$3,550 | — | 0.0 |
| Lung Cancer | 85 (52–132) | 329 | 2 | ≈$3,390 | — | 0.0 |
| Translational Lung Cancer Research | 86 (60–111) | 379 | 57 | — | Open access | 0.0 |
| Cancer Epidemiology | 86 (65–128) | 187 | 7 | ≈$3,740 | Hybrid | 0.0 |
| Oncology | 87 (67–134) | 97 | 20 | — | — | 0.0 |
| Journal of Thoracic Oncology | 88 (55–128) | 104 | 7 | ≈$4,100 | — | 0.0 |
| Cancer Immunology Immunotherapy | 91 (61–142) | 333 | 26 | $4,790 | Open access (DOAJ) | 0.0 |
| Journal of Cancer Survivorship | 91 (64–137) | 216 | 19 | ≈$4,790 | — | 0.0 |
| International Journal of Clinical Oncology | 92 (61–131) | 250 | 17 | ≈$4,590 | — | 0.0 |
| Journal of Gastrointestinal Oncology | 92 (64–115) | 230 | 68 | — | Open access | 0.0 |
| Annals of Gastroenterological Surgery | 92 (67–117) | 163 | 15 | $2,421 | Open access (DOAJ) | 0.0 |
| Seminars in Oncology Nursing | 92 (53–124) | 124 | 28 | ≈$3,590 | — | 0.0 |
| The Breast | 93 (66–129) | 213 | 2 | $3,770 | Open access (DOAJ) | 0.0 |
| Clinical Breast Cancer | 93 (69–143) | 197 | 4 | ≈$3,470 | — | 0.0 |
| The Journal of Pathology Clinical Research | 93 (61–136) | 54 | — | $3,570 | Open access (DOAJ) | 0.0 |
| Oncology Reviews | 93 (67–137) | 52 | 20 | ≈$2,383 | Open access (DOAJ) | — |
| World Journal of Clinical Oncology | 96 (73–119) | 218 | — | — | Open access | 0.0 |
| Cancer Drug Resistance | 96 (69–117) | 63 | 12 | — | Open access | 0.0 |
| Exploration of Targeted Anti-tumor Therapy | 97 (74–111) | 65 | 21 | $2,000 | Open access (DOAJ) | 0.0 |
| Clinical & Experimental Metastasis | 97 (73–158) | 61 | 21 | ≈$5,090 | — | 0.0 |
| ESMO Open | 98 (65–133) | 323 | 37 | $4,310 | Open access (DOAJ) | 0.0 |
| Med | 98 (5–163) | 156 | 31 | ≈$9,350 | — | 0.0 |
| Bulletin du Cancer | 98 (64–139) | 123 | 67 | ≈$1,790 | — | 1.47 |
| Asia-Pacific Journal of Oncology Nursing | 102 (77–130) | 176 | 5 | $2,480 | Open access (DOAJ) | 0.0 |
| Cancer Chemotherapy and Pharmacology | 106 (77–139) | 107 | 25 | ≈$4,390 | — | 4.97 |
| Cancer Research and Treatment | 107 (71–151) | 167 | 1 | — | Open access | 1.53 |
| Cancer Management and Research | 109 (86–140) | 278 | 14 | $3,940 | Open access (DOAJ) | 18.57 |
| Pancreas | 109 (64–172) | 160 | 159 | — | — | 0.0 |
| Breast Cancer Targets and Therapy | 110 (85–142) | 107 | 13 | $4,320 | Open access (DOAJ) | 0.0 |
| Journal of the Anus Rectum and Colon | 110 (76–146) | 50 | 106 | ≈$1,290 | Open access (DOAJ) | 0.0 |
| Molecular and Clinical Oncology | 111 (90–148) | 102 | 31 | — | Open access | 0.0 |
| ImmunoTargets and Therapy | 111 (89–133) | 94 | 13 | $4,320 | Open access (DOAJ) | — |
| International Journal of Colorectal Disease | 111 (67–160) | 86 | 17 | ≈$3,790 | — | 0.0 |
| Chinese Clinical Oncology | 111 (84–139) | 80 | — | — | Open access | 0.0 |
| Clinical Lung Cancer | 113 (81–145) | 171 | 4 | ≈$3,200 | Hybrid | 0.0 |
| Colorectal Disease | 113 (78–150) | 164 | — | ≈$4,480 | — | 0.0 |
| JTO Clinical and Research Reports | 113 (83–157) | 113 | 7 | $2,000 | Open access (DOAJ) | 0.0 |
| BJS Open | 114 (63–156) | 178 | — | ≈$2,805 | Open access (DOAJ) | 0.0 |
| Breast Cancer | 115 (78–153) | 139 | 13 | ≈$3,890 | — | 0.0 |
| Therapeutic Advances in Medical Oncology | 118 (93–151) | 271 | 38 | $2,800 | Open access (DOAJ) | 0.0 |
| JNCI Cancer Spectrum | 118 (77–153) | 122 | — | $1,951 | Open access (DOAJ) | 0.0 |
| Cancer Science | 120 (83–148) | 276 | 15 | $2,600 | Open access (DOAJ) | 1.74 |
| Cancer and Metastasis Reviews | 122 (99–164) | 69 | 13 | ≈$3,790 | — | 0.0 |
| Pancreatology | 124 (78–196) | 155 | 2 | ≈$4,000 | Hybrid | 0.0 |
| Cancer Epidemiology Biomarkers & Prevention | 127 (102–167) | 253 | — | — | Hybrid | 0.0 |
| Journal of Geriatric Oncology | 127 (80–184) | 168 | 10 | ≈$3,610 | Hybrid | 0.0 |
| Cancer Causes & Control | 130 (82–198) | 162 | 19 | ≈$3,890 | — | 0.0 |
| Cancer Treatment and Research Communications | 131 (80–205) | 215 | 2 | $2,940 | Open access (DOAJ) | 2.79 |
| BMC Cancer | 132 (86–236) | 2,045 | 20 | $3,550 | Open access (DOAJ) | 1.07 |
| Psycho-Oncology | 132 (89–195) | 283 | — | ≈$4,940 | — | 0.0 |
| Breast Cancer Research | 134 (89–180) | 246 | 22 | $4,190 | Open access (DOAJ) | 1.3 |
| The Oncologist | 135 (88–196) | 399 | — | $3,668 | Open access (DOAJ) | 0.0 |
| Clinical Cancer Research | 137 (103–185) | 502 | — | — | Hybrid | 0.0 |
| Clinical Medicine Insights Oncology | 138 (120–169) | 64 | 40 | $2,650 | Open access (DOAJ) | 0.0 |
| Cancer Research Communications | 140 (102–182) | 192 | — | $2,550 | Open access (DOAJ) | 0.0 |
| Journal of the National Comprehensive Cancer Network | 140 (111–179) | 118 | 138 | — | — | 0.0 |
| Translational Oncology | 148 (99–204) | 375 | 8 | $3,880 | Open access (DOAJ) | 0.0 |
| International Journal of Cancer | 154 (118–197) | 473 | 16 | ≈$5,030 | Hybrid | 0.0 |
| npj Breast Cancer | 155 (107–223) | 169 | 23 | $3,890 | Open access (DOAJ) | 0.0 |
| Cancer Discovery | 159 (20–234) | 174 | — | — | Hybrid | 0.0 |
| npj Precision Oncology | 164 (118–219) | 461 | 21 | $4,290 | Open access (DOAJ) | 0.0 |
| Molecular Therapy Oncology | 165 (117–193) | 116 | 3 | $3,900 | Open access (DOAJ) | 0.0 |
| Cancer Medicine | 169 (117–244) | 883 | — | $4,970 | Open access (DOAJ) | 0.4 |
| Supportive Care in Cancer | 177 (132–254) | 1,048 | 13 | ≈$4,690 | — | 0.0 |
| British Journal of Cancer | 184 (146–236) | 344 | 23 | ≈$5,190 | Hybrid | 0.0 |
| JMIR Cancer | 202 (143–276) | 151 | 53 | $1,985 | Open access (DOAJ) | 0.0 |
| Cancer Cell | 206 (31–307) | 203 | 23 | ≈$10,400 | Hybrid | 0.0 |
| Molecular Cancer Therapeutics | 209 (157–271) | 174 | — | — | Hybrid | 0.0 |
| Cancer Immunology Research | 224 (153–303) | 136 | — | — | Hybrid | 0.0 |
| Asia-Pacific Journal of Clinical Oncology | 250 (118–368) | 84 | 16 | ≈$3,700 | — | 0.0 |
| Nature Cancer | 336 (253–467) | 109 | 43 | ≈$12,690 | Hybrid | 0.0 |
Journals are listed where at least 25% of their articles' topics fall in Oncology (OpenAlex).
Latest available year: 2024
5 journals without enough usable 2025 data. Their 2024 figures are shown separately so they are never compared with 2025 figures.
| Open access | ||||||
|---|---|---|---|---|---|---|
| Clinical Colorectal Cancer | 76 (42–196) | 58 | 6 | ≈$3,690 | — | 0.0 |
| Pathology & Oncology Research | 81 (52–120) | 66 | 15 | $2,500 | Open access (DOAJ) | 9.82 |
| JNCI Monographs | 81 (62–114) | 51 | — | — | — | — |
| BJC Reports | 103 (72–151) | 76 | 36 | $2,790 | Open access (DOAJ) | — |
| Journal of the National Cancer Center | 145 (94–208) | 56 | 12 | $2,700 | Open access (DOAJ) | — |
Latest available year: 2023
2 journals without enough usable 2025 data. Their 2023 figures are shown separately so they are never compared with 2025 figures.
| Open access | ||||||
|---|---|---|---|---|---|---|
| Cancer Innovation | 74 (52–107) | 55 | 54 | $2,700 | Open access (DOAJ) | — |
| Journal of Immunotherapy | 133 (80–186) | 52 | 39 | — | Hybrid | 0.0 |
Latest available year: 2022
1 journal without enough usable 2025 data. Their 2022 figures are shown separately so they are never compared with 2025 figures.
| Open access | ||||||
|---|---|---|---|---|---|---|
| European Journal of Cancer Care | 203 (140–319) | 191 | 17 | ≈$2,490 | — | 0.0 |
Latest available year: 2021
1 journal without enough usable 2025 data. Their 2021 figures are shown separately so they are never compared with 2025 figures.
| Open access | ||||||
|---|---|---|---|---|---|---|
| JCO Precision Oncology | 142 (99–199) | 108 | 40 | — | Hybrid | 0.89 |
Latest available year: 2020
1 journal without enough usable 2025 data. Their 2020 figures are shown separately so they are never compared with 2025 figures.
| Open access | ||||||
|---|---|---|---|---|---|---|
| Cancer Biology and Medicine | 110 (89–130) | 74 | — | $2,800 | Open access (DOAJ) | 0.0 |
Have a deadline?
Pick up to five journals and see whether a submission sequence can realistically reach acceptance before your defence, visa or job-market date. Free.
Open the submission plannerFrequently asked questions
Which Oncology journals accepted papers fastest in 2025?
Among 98 Oncology journals with enough dated articles in 2025, the shortest median time from submission to acceptance was 0 days (Anti-Cancer Drugs). The middle journal's median was 98 days. Speed is not a measure of quality; check scope, indexing and fees too.
How are these times measured?
From the submission and acceptance dates publishers deposit in PubMed, for accepted articles only. Each journal needs at least 50 dated articles in the year shown, and a table headed with a year contains only that year's figures.
Get the free Journal Submission Go/No-Go Checklist
The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.
Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.